Does Peritoneal Membrane Transport Affect Peritoneal Clearance of Beta 2–Microglobulin in Peritoneal Dialysis Patients? by Akçakaya, Mesut et al.
Turk Neph Dial Transpl 2013; 22 (1): 101-105
101
özgün	araştırma/Original	ınvestigation
Does Peritoneal Membrane Transport Affect Peritoneal Clearance of 
Beta 2–Microglobulin in Peritoneal Dialysis Patients?
Periton Diyalizi Hastalarında Periton Membran Transportu Beta-2 
Mikroglobülinin Periton Klirensini Etkiler mi?
mesut	aKÇaKaYa
Oktay	OYmaK
Feridun	KaVunCuOğlu
aydın	Ünal
Bülent	TOKGöz
Cengiz	uTaş
Erciyes University, Faculty of Medicine, 
Department of Nephrology,
Kayseri, Turkey
aBSTRaCT
OBJECTıVE: Our aim in this study was to compare peritoneal clearance of beta 2-microglobulin 
(B2M) in peritoneal dialysis (PD) patients who had high and low membrane transport status.
maTERıal	and	mETHOdS: Forty-nine PD patients were included in this study. The patients were 
divided into two groups according to their peritoneal equilibration test (PET) results; high transport 
group and low transport group. Serum B2M levels and peritoneal clearance of B2M were compared 
between the two groups.
RESulTS: Dialysate B2M level and peritoneal clearance of B2M were higher in the high transporter 
group than in the low transporter group (5.92 ± 2.62 mg/L vs. 3.42 ± 1.51 mg/L, p: <0.001 and 11.13 
± 2.14 L/week/1.73 m2 vs. 6.41 ± 1.65 L/week/1.73 m2, p: <0.001, respectively). On the other hand, 
there was no significant difference in serum B2M concentration between the high transport group and 
the low transport group (24.15 ± 9.10 mg/L vs. 27.35 ± 10.10 mg/L, respectively, P>0.05). Serum B2M 
concentration was positively correlated with duration of PD (r: 0.518, p: <0.001).
COnCluSıOn: Although dialysate levels and peritoneal clearance of the middle molecule B2M 
were significantly higher in high transporters compared to low transporters, there was no significant 
difference between the two groups in terms of serum B2M concentration.
KEY	wORdS: Beta-2 microglobulin, High transporter, Low transporter, Middle molecule, Peritoneal 
clearance
öz
amaÇ: Bu çalışmada, yüksek ve düşük geçirgen membran transport özelliğine sahip periton diyalizi 
(PD) hastalarında beta 2-mikroglobülinin (B2M) periton klirenslerini karşılaştırmayı amaçladık. 
GEREÇ	ve	YönTEmlER:	Kırk dokuz PD hastası çalışmaya alındı. Hastalar periton eşitleme testi 
(PET) sonuçlarına göre iki gruba ayrıldı; yüksek geçirgen grup ve düşük geçirgen grup. İki grup 
arasında serum B2M düzeyleri ve B2M’nin periton klirensleri karşılaştırıldı. 
BulGulaR: Diyalizat B2M düzeyi ve B2M’nin periton klirensleri yüksek geçirgen grupta düşük 
geçirgen  gruba  kıyasla  daha  yüksekti  (sırasıyla  5,92  ±  2,62  mg/L’ye  karşın  3,42  ±  1,51mg/L,  p: 
<0,001 ve 11,13 ± 2,14 L/hafta/1,73 m2 vs. 6,41 ± 1,65, L/hafta/1,73 m2, p: <0,001). Öte yandan 
yüksek geçirgen grup ile düşük geçirgen grup arasında serum B2M konsantrasyonu açısından anlamlı 
fark saptanmadı (sırasıyla 24,15 ± 9,10 mg/L’ye karşın 27,35 ± 10,10 mg/L, P>0,05). Serum B2M 
konsantrasyonu PD süresi ile ilişkiliydi (r: 0,518, p: <0,001).
SOnuÇ: Orta molekül ağırlıklı molekül olan B2M’nin diyalizat düzeyleri ve periton klirensleri yüksek 
geçirgenlerde düşük geçirgenlere kıyasla anlamlı olarak daha yüksek olmasına rağmen, serum B2M 
konsantrasyonu açısında iki grup arasında anlamlı fark yoktu.
anaHTaR	SözCÜKlER: Beta 2-mikroglobulin, Yüksek geçirgen, Düşük geçirgen, Orta molekül 
Ağırlıklı molekül, Periton klirensi
doi: 10.5262/tndt.2013.1001.15
Correspondence Address:
aydın	Ünal
Erciyes Üniversitesi Tıp Fakültesi, 
Nefroloji Bilim Dalı, Kayseri, Turkey
Phone  : +90 352 437 93 49
E-mail  : aydinunal2003@gmail.com
Received  : 21.03.2012
Accepted  : 16.07.2012Akçakaya M et al : Does Peritoneal Membrane Transport Affect Peritoneal 
Clearance of Beta 2–Microglobulin in Peritoneal Dialysis Patients?
Turk Neph Dial Transpl 2013; 22 (1): 101-105
102
Türk	nefroloji	diyaliz	ve	Transplantasyon	dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
patients. Peritoneal transport of creatinine was measured using 
a  4-hour  sample  during  standardized  PET  (12).  Because  the 
number of patients was low, the patients were divided into two 
groups according to their PET results; high transport group (n: 
25; only high) and low transport group [n: 24 (14 low; 10 low 
average)].
Serum albumin, glucose, blood urea nitrogen, and creatinine 
and dialysate creatinine and glucose were measured by using 
routine laboratory methods.
Dialysate  B2M  level  was  measured  with  4-hour  samples 
during  PET.  The  serum  B2M  level  was  also  evaluated 
concurrently.  The  serum  and  dialysate  B2M  levels  were 
determined  with  Beckman  Coulter  Immage  Nephelometry 
system (Fullerton, CA).
PD dialysate samples for a period of 24 hours were obtained 
and  dialysate  urea,  creatinine,  and  B2M  clearances  were 
calculated. All clearances were normalized to 1.73 m² of body 
surface area (BSA).
Anuria was defined as 24-h urine output < 100 mL and/
or residual GFR < 1 mL/min. Five of the 49 PD patients were 
anuric. Among the anuric patients 3 were high transporter and 2 
were low transporter.
Peritoneal, renal, and total Kt/Vurea were calculated 
according  to  National  Kidney  Foundation  Kidney  Disease 
Outcomes Quality Initiative guidelines (13).
Statistical	analysis
Statistical  analysis  was  performed  by  using  Statistical 
Package for the Social Sciences (SPSS) 15.0 for Windows. The 
Kolmogorov-Smirnov test was used to determine normality of 
distributions  of  variables.  Continuous  variables  with  normal 
distribution are presented as mean ± standard deviation. The 
median value was used where normal distribution was absent. 
Statistical analysis for the parametric variables was performed 
using  the  Student’s  t-test  between  two  groups.  The  Mann-
Whitney U test was used to compare nonparametric variables 
between  two  groups. The  correlation  analysis  was  evaluated 
by  Spearman’s  correlation  test  for  nonparametric  variables. 
Qualitative variables are given as percent and the correlation 
between categorical variables was investigated using the chi-
square  test  and  Fisher’s  exact  test. A  p  value  of  <0.05  was 
considered significant.
RESulTS
The  etiology  of  end-stage  renal  disease  (ESRD)  was 
hypertension  in  18  (36.7%),  diabetes  mellitus  in  11  (22.4), 
nephrolithiasis  in  2  (4.1%),  amyloidosis  in  2  (4.1%), 
glomerulonephritis in 1 (2.0%), polycystic kidney disease in 1 
(2.0%), and others/unknown in 14 (28.6%).
Demographic and clinical findings of the patients are shown 
in Table  I. There  was  no  significant  difference  between  two 
ınTROduCTıOn
Beta  2-microglobulin  (B2M),	 a  prototype  of  middle-
molecule  uremic  toxins,  is  a  low  molecular  weight  protein 
(11800  Da),  which  is  produced  by  all  cells  expressing  the 
major histocompatibility class I antigens. Under physiological 
conditions, B2M is generated at a constant rate, except in patients 
with systemic inflammation and haematopoietic neoplasia (1). 
It is produced at 150-200 mg per day and eliminated from 
the circulation through the renal pathway (2). B2M is filtered 
by the glomerulus and is degenerated in the proximal tubules 
through  a  megalin-dependent  pathway  (3).  Circulating  B2M 
levels  are  elevated  in  patients  with  a  reduced  glomerular 
filtration rate (GFR). In dialysis patients, in whom GFR is almost 
completely  abolished,  B2M  accumulates  in  the  circulation. 
Although it remains unknown whether the B2M molecule itself 
is a uremic toxin, B2M has been considered to be a surrogate 
marker of putative middle-molecule uremic toxins, which are 
difficult to dialyze by use of a low flux membrane (4). It has 
been  demonstrated  that  elevated  concentration  of  circulating 
B2M is a potential risk for the development of dialysis-related 
amyloidosis (5). Advanced glycosylation end product (AGE) 
may  affect  the  pathophysiological  impact  of  B2M.  AGE-
modified  B2M  has  been  identified  in  amyloid  deposits  in 
hemodialysis (HD) patients (6). AGE also enhances monocyte 
migration and cytokine secretion (7), suggesting that AGE-B2M 
may  initiate  an  inflammatory  response,  leading  to  bone/joint 
destruction (6-7).
It has been reported that serum B2M levels are lower in 
peritoneal dialysis (PD) patients than in HD patients [8]. This 
may be due to better conservation of residual renal function 
with  PD,  because  PD  alone  poorly  clears  B2M  [9].  Several 
methods to reduce plasma B2M levels including the use of high-
flux membrane, ultrapure dialysate [4], hemodiafiltration [10-
11], and the absorptive affinity column for B2M [5] have been 
attempted in dialysis patients. Peritoneal clearance of B2M and 
serum B2M levels in PD patients was evaluated in a few studies. 
Our aim in this study was to compare serum B2M levels and 
peritoneal clearance of B2M in PD patients who had high and 
low membrane transport status.
maTERıal	and	mETHOdS
This study was performed at the Department of Nephrology, 
Erciyes University Medical School between January 2007 and 
December  2008.  Forty-nine  (25  males  and  24  females)  PD 
patients were included in this study. Thirty-eight of 49 patients 
were on continuous ambulatory peritoneal dialysis and the rest 
were on automated peritoneal dialysis. Patients who had acute 
illness, significant infection or malignancy, were excluded from 
the study. The study protocol was approved by the local ethics 
committee. The study procedures were approved by all patients.
The peritoneal equilibration test (PET) was performed in all 103
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significantly lower in high transporters than in low transporters. 
On the other hand, dialysate B2M level and peritoneal clearance 
of  creatinine  and  B2M  were  significantly  lower  in  low 
transporters than in high transporters. There was no significant 
difference between two groups with regard to serum B2M level, 
total Kt/Vurea value, and peritoneal clearance of urea.
groups with regard to age, gender, weight, BSA, duration of PD, 
24-h urine output, and underlying renal disease (p>0.05). Table 
II demonstrates comparison of biochemical findings between 
high  transporters  and  low  transporters.  Serum  albumin  level 
and gradient of B2M, which denotes a gap between serum and 
dialysate B2M levels at 4-hour samples during the PET, were 
Table	ı: Demographic and clinical findings of the patients.
Parameter	 High	transporter	(n:	25)	 low	transporter	(n:	24)	 P	value	
Age (years)  50.96 ± 14.76  44.58 ± 16.97  0.167 
Male/female  15/10 10/14 0.159 
Weight (kg)  66.00 ± 15.26  65.20 ±13.29  0.844 
Body surface area (m2)  1.70 ± 0.21  1.70 ± 0.19  0.897 
PD duration (month)  28 (3-131)  34 (1-132)  0.522 
24-h urine output (mL)  1261 ± 660  924 ± 719  0.168 
Etiology of ESRD  0.533 
Hypertension  9  9 
Diabetes mellitus  7  4 
Nephrolithiasis  1  1 
Amyloidosis  2  -
Glomerulonephritis  - 1 
Polycystic kidney disease  - 1 
Others/unknown  6  8 
Pd: peritoneal dialysis, ESRd: end-stage renal disease
Table	ıı:	Comparison of biochemical findings between high transporters and low transporters.
Parameter	 High	transporter	(n:	25)	 low	transporter	(n:	24)	 P	value	
Serum albumin (g/dL)  2.66 ± 0.64  3.17 ± ± 0.45  0.003 
Serum B2M (mg/L)  24.1 ± 9.10  27.55 ± 10.10  0.248 
Dialysate B2M (mg/L)  5.92 ± 2.62  3.42 ± 1.51  <0.001 
Gradient of B2M*  18.23 ± 7.86  23.93 ± 8.98  0.022 
Total Kt/Vurea  2.75 ± 0.83  2.57 ± 0.59  0.376 
Peritoneal clearance of 
creatinine (L/week/1.73m²)  55.58 ± 9. 63  50.17 ± 6.48  0.026 
urea (L/week/1.73m²)  64.22 ± 14.03  66.87 ± 8.02  0.420 
B2M (L/week/1.73m²)  11.13 ± 2.14  6.41 ± 1.65  <0.001 
B2M: Beta-2 microglobulin 
* Gradient of B2M denotes a gap between serum and dialysate B2M levels at 4-hour sample during the peritoneal equilibration testAkçakaya M et al : Does Peritoneal Membrane Transport Affect Peritoneal 
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(14). In our study, we found that dialysate B2M concentration 
and peritoneal clearance of B2M were significantly higher in 
high  transporters  than  in  low  transporters.  Individual  patient 
peritoneal membrane transport characteristics are important in 
determining total solute clearance and ultrafiltration rates in PD 
patients. High transporters tend to optimize both solute clearance 
and ultrafiltration after a short dwell time (21) but they are less 
successful in the removal of middle molecules. Although they 
would easily reach total solute clearance goals, it has recently 
been shown that these patients have an increased relative risk of 
death and a decreased technique survival (22).
Although there was no significant difference, serum B2M 
level was lower in high transporters than in low transporters. 
However, the dialysate B2M level was significantly higher in 
high transporters than in low transporters. On the other hand, the 
gradient of B2M was significantly higher in low transporters than 
in high transporters. These observations indicate that peritoneal 
B2M permeability increases if peritoneal permeability increases 
and  supports  the  finding  that  dialysate  B2M  levels  were 
significantly higher in high transporters than in low transporters.
There were some limitations of the present study. Firstly, 
the results were based on a small number of patients, and our 
findings should be validated with further studies. Secondly, it 
is possible that we could not fully control for all confounding 
variables  which  affect  production  and  clearance  of  B2M.  In 
addition, the influence of B2M and peritoneal clearance of B2M 
on morbidity and mortality should be examined in PD patients 
in future studies.
In  conclusion,  we  demonstrated  that  dialysate  B2M 
concentration  and  peritoneal  clearance  of  B2M  were  higher 
in high transporters than low transporters in the present study. 
However, this increased peritoneal clearance of B2M in the high 
transporter PD group lead only to statistically insignificantly 
lower serum levels of B2M compared to the low transporter PD 
group.
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